Camber Pharmaceuticals lawsuits center on two large active matters: a multidistrict litigation over cancer-causing contamination in its generic valsartan blood pressure pills, and a 44-state antitrust case accusing the company and its president of helping fix generic drug prices. Camber has also settled economic-loss claims tied to the valsartan recall, won a patent infringement suit brought against it, and paid small federal penalties for late Medicaid rebate payments.1Research file
The Valsartan Cancer Lawsuits
The largest legal exposure Camber faces comes from thousands of personal injury suits alleging that its generic valsartan tablets contained N-Nitrosodimethylamine (NDMA), a probable human carcinogen, and caused cancers including liver, colon, stomach, and blood cancers. The contamination traced back to the active pharmaceutical ingredient supplied by Camber’s Indian parent, Hetero Labs Limited.1Research file
Camber issued a voluntary nationwide recall of all unexpired lots of its valsartan tablets in August 2018, covering the 40mg, 80mg, 160mg, and 320mg strengths. It followed in February 2019 with a recall of 87 lots of losartan potassium tablets after a related nitrosamine impurity, NMBA, turned up in the Hetero-made ingredient. Camber reported no adverse events at the time of either recall.1Research file
The FDA’s own risk estimate framed the scale of the problem: if 8,000 people took the highest daily dose of contaminated valsartan for four years, roughly one additional cancer case could result beyond the background rate. That figure, applied across millions of prescriptions filled over years, is what drove the wave of individual suits.1Research file
Where the MDL Stands
The cases are consolidated as In Re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, MDL No. 2875, in the U.S. District Court for the District of New Jersey before Chief Judge Renée Marie Bumb. Camber is listed among the defendants alongside Hetero and other manufacturers and distributors. Roughly 1,350 cases remained active in the MDL as of late 2025.1Research file
Six cases were selected as bellwethers to test both sides’ arguments. The first, Gaston Roberts v. ZHP, et al., was scheduled for September 2025 but never reached a jury. In November 2025, Judge Bumb excluded the plaintiff’s sole specific-causation expert as unreliable under Federal Rule of Evidence 702 as amended in 2023 and granted summary judgment for the defendants. A second bellwether wave is still in preparation after deadline extensions granted in August 2025.1Research file
The Roberts ruling was a defense win, but earlier decisions cut the other way. In December 2022, an earlier judge allowed plaintiffs’ general expert testimony linking NDMA to cancer to proceed. In March 2024, the court ruled that the defendants’ labeling and statements about their generic valsartan products constituted an “express warranty,” a finding that plaintiffs can lean on in future trials.1Research file
The Hetero Economic-Loss Settlement
One piece of the valsartan litigation has resolved for consumers, though only for economic losses rather than personal injury. A class action settlement of approximately $11.37 million covers the “Hetero Defendants,” a group that explicitly includes Camber Pharmaceuticals along with Hetero Drugs Ltd., Hetero Labs Ltd., and Hetero USA Inc.1Research file
The class covers consumers who bought valsartan medications made using Hetero’s “Process III” active ingredient between May and July 2018. Payments run up to $40 per 30-day supply purchased, capped at $120 per class member. A final approval hearing was scheduled for June 30, 2026.1Research file
No comparable settlement has been announced for the main personal injury claims against any defendant in the MDL. A separate motion for a class settlement involving irbesartan claims against manufacturer Aurobindo was filed in October 2025. Plaintiffs have also sought sanctions against Chinese manufacturer Zhejiang Huahai Pharmaceutical for allegedly destroying discovery documents.1Research file
The Generic Drug Price-Fixing Case
Camber and its president, Kon Ostaficiuk, are named defendants in a sprawling antitrust suit filed in 2019 by 44 states and Puerto Rico. Led by the attorneys general of Connecticut, Florida, and New York, the complaint accuses Teva Pharmaceuticals, Camber, and 18 other generic manufacturers of a coordinated conspiracy to fix prices, allocate markets, and rig bids on more than 100 generic drugs. Prosecutors described price increases that in some cases exceeded 1,000 percent. Ostaficiuk is one of 15 individual senior executives named.1Research file
The states’ complaint quoted phrases allegedly used among industry executives, including “fair share,” “playing nice in the sandbox,” and “responsible competitor.” The coalition seeks damages, civil penalties, and orders to restore competition.1Research file
The case is consolidated in the U.S. District Court for the District of Connecticut before Judge Michael P. Shea. It has produced a mix of settlements and contested rulings, though none resolving Camber’s exposure. Apotex settled for $39.1 million and Heritage for $10 million, and seven individual pharmaceutical executives have reached their own settlements. In May 2026, Judge Shea approved a $17.9 million settlement between Bausch Health, Lannett, and 48 state and territorial governments. In December 2025, he denied a defense summary judgment motion in a related topical-drugs case, finding the states had presented substantial evidence from which a jury could infer widespread price coordination.1Research file
Whether Camber or Ostaficiuk will settle or go to trial is still unclear. In April 2026 the states asked for a three-month pause in deadlines to negotiate with remaining defendants; Judge Shea denied that request. The available record does not indicate criminal charges against Camber or Ostaficiuk in the parallel Justice Department investigation, which has secured guilty pleas and deferred prosecution agreements from other companies.1Research file
The Roxane Laboratories Patent Suit
Not every case has gone against Camber. Roxane Laboratories sued Camber and co-defendant InvaGen Pharmaceuticals for allegedly infringing U.S. Patent No. 8,563,032, which covered a calcium acetate capsule formulation used to treat kidney failure. The patent specified capsules of “size 00 or less.” Camber’s product used an elongated “size 00el” capsule, physically larger than the standard size 00.1Research file
The District of New Jersey ruled that “size 00” referred to a specific dimension, not a family of capsules, so the elongated version fell outside the patent. The Federal Circuit affirmed twice: in March 2015 it upheld the denial of Roxane’s preliminary injunction without opinion, and in November 2016 it affirmed the claim construction on the merits, finding the patent’s intrinsic record “unambiguously and fully” resolved the question.1Research file
In April 2017, the district court declared the litigation “exceptional” under federal patent law, calling Roxane’s infringement theory “objectively meritless” and unsupported by established claim construction principles. The court granted Camber and InvaGen’s motion for attorney’s fees. The defendants sought over $2.1 million in fees and costs.1Research file
Other Recalls and Regulatory Actions
Two additional recalls sit alongside the litigation. In August 2018, Camber recalled a single lot of bottles labeled as montelukast sodium tablets (an asthma medication) after finding they actually contained losartan potassium tablets (a blood pressure drug). The FDA warned the mix-up posed particular danger to pregnant women, since losartan can cause fetal harm. Camber reported no adverse events. In March 2023, the company recalled one lot of atovaquone oral suspension over potential contamination with Bacillus cereus, a bacterium that can cause gastrointestinal illness. Again, no adverse events were reported.1Research file
The Centers for Medicare and Medicaid Services has imposed two small civil monetary penalties on Camber for late or missing payments under the Medicaid Drug Rebate Program: $3,385 in January 2024 for the third quarter of 2023 and $480 in April 2024 for the fourth quarter.1Research file
Camber itself has not received an FDA warning letter, but its parent’s Indian facilities have. In August 2017, the FDA warned Hetero Labs Unit V in Telangana over failures to investigate batch discrepancies, equipment contamination, and a months-long delay in recalling defective finasteride tablets. In September 2025, inspectors visited a Hetero warehouse in Visakhapatnam and issued a Form 483 with six observations, reporting that they were denied entry for two hours, that birds, lizards, and cats were roaming the facility, that bird droppings sat on drug ingredient drums, and that containers were damaged with torn labels and open lids. Hetero had no pest control procedures in place. A related inspection of Hetero’s Unit IX facility in Andhra Pradesh that same month produced another six-observation Form 483, citing an unregistered testing laboratory, undocumented release of finished ingredients to an offsite warehouse, and discrepancies between raw material records and production yields. These findings at the parent’s facilities carry potential implications for the quality of ingredients supplied to Camber for the U.S. market.1Research file